Literature DB >> 9124825

Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem.

C Ponte1, A Parra, E Nieto, F Soriano.   

Abstract

Acute respiratory infection with penicillin-insensitive Streptococcus pneumoniae (MIC and MBC, 1 and 2 micrograms/ml, respectively) was established in guinea pigs. Intratracheal instillation of 0.5 ml of an overnight culture of S. pneumoniae concentrated 25 times (approximately 3 x 10(9) CFU) induced a bacteremic and fatal pneumonia in > 85% of untreated animals within 46 h, with a mean +/- standard deviation bacterial count of 8.83 +/- 1.11 log10 CFU in lung homogenates. This model was used to evaluate the efficacies of two doses each of amoxicillin, cefotaxime, and meropenem given 1 h after bacterial inoculation. The antibiotics were given at 8-h intervals for up to a total of four injections. The dose of 50 mg of any antibiotic per kg of body weight gave 66.6% survival, compared with 5.05% survival for untreated control animals (P < 0.001). A dose of 200 mg/kg gave a survival rate of 77.8% for meropenem and 83.3% for amoxicillin and cefotaxime, while survival for untreated controls was 11.1% (P < 0.001). Although antibiotic treatment decreased mortality compared with that in untreated controls, the antibiotics contributed to a high early (less than 9 h after bacterial inoculation) mortality, being 53.5% compared with only 6.06% for the untreated controls (P < 0.001). Quantitative cultures of the lungs of animals that died during the 46-h observation period or that were killed after this time showed a significant reduction in the numbers of organisms among treated animals compared with numbers among the control animals (P < 0.001). The described model is an appropriate system for evaluating antibiotic efficacy in invasive pulmonary infection caused by penicillin-insensitive S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124825      PMCID: PMC163606     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Survival after intramuscular or inhalation administration of gentamicin in neutropenic guinea pigs infected by Klebsiella pneumoniae.

Authors:  T Trnovec; Z Kállay; M Durisová; S Bezek; J Navarová
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis.

Authors:  E Tuomanen; B Hengstler; R Rich; M A Bray; O Zak; A Tomasz
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

4.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 5.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

6.  Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression.

Authors:  J E Pennington; M G Ehrie
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

7.  The disposition and metabolism of meropenem in laboratory animals and man.

Authors:  M P Harrison; S R Moss; A Featherstone; A G Fowkes; A M Sanders; D E Case
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Penetration into lung tissue after intravenous administration of amoxycillin/clavulanate.

Authors:  A L Cox; J M Meewis; R Horton
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

9.  Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia.

Authors:  F M Gordin; M G Rusnak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Timing of penicillin treatment influences the course of Streptococcus pneumoniae-induced middle ear inflammation.

Authors:  K Sato; M K Quartey; C L Liebeler; G S Giebink
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  9 in total

1.  In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media.

Authors:  C Cenjor; C Ponte; A Parra; E Nieto; G García-Calvo; M J Giménez; L Aguilar; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

2.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.

Authors:  Matilde Gracia; Carmina Martínez-Marín; Lorena Huelves; Maria J Giménez; Lorenzo Aguilar; Antonio Carcas; Carmen Ponte; Francisco Soriano
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

5.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Retrospective analysis of the efficacies of two different regimens of aqueous penicillin G administered to children with pneumonia.

Authors:  Alyson Brandão; Raquel Simbalista; Igor C Borges; Dafne C Andrade; Marcelo Araújo; Cristiana M Nascimento-Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 8.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

Review 9.  Port d'Entrée for Respiratory Infections - Does the Influenza A Virus Pave the Way for Bacteria?

Authors:  Nikolai Siemens; Sonja Oehmcke-Hecht; Thomas C Mettenleiter; Bernd Kreikemeyer; Peter Valentin-Weigand; Sven Hammerschmidt
Journal:  Front Microbiol       Date:  2017-12-21       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.